Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: A population-based epidemiological study

British Journal of Cancer

Volumn 79, Issue 5-6, 1999, Pages 927-932

  Lenner, P ^a   Wiklund, F ^a   Emdin, S O ^a   Arnerlov C ^a   Eklund, C ^b   Hallmans, G ^a   Zentgraf, H ^c   Dillner, J ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antibodies; Breast cancer; Case control study; p53; Survival

Indexed keywords

AUTOANTIBODY; PROTEIN P53;

ADULT; AGE; ANTIBODY BLOOD LEVEL; ARTICLE; BREAST CANCER; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; SURVIVAL RATE; WESTERN BLOTTING;

ADULT; AUTOANTIBODIES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SWEDEN; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033037360     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690148     Document Type: Article

References (32)

1. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK and Mcguire WL (1993a) Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206
2. Allred DC, Clark GM, Fuqua SAW, Elledge RM, Hilsenbeck SG, Ravdin PM, Yee D, Chamness GC and Osborne CK (1993b) Overexpression of p53 in node-positive breast cancer. Breast Cancer Res Treat 27: 131
3. Barnes DM, Dublin EA, Fisher CJ, Levison DA and Millis RR (1993) Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 24: 469-476
4. Coomber D, Hawkins NJ, Clark M, Meagher A and Ward RL (1996) Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer. J Cancer Res Clin Oncol 122: 757-762
5. Crawford LV, Pim DC and Bulbrook RD (1982) Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30: 403-408
6. Davidoff AM, Kerns BJM, Iglehart JD and Marks JR (1991a) Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 51: 2605-2610
7. Davidoff AM, Humphrey PA, Iglehart JD and Marks JR (1991b) Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 88: 5006-5010
8. Davidoff AM, Iglehart JD and Marks JR (1992) Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89: 3439-3442
9. Green JA, Mudenda B, Jenkins J, Leinster SJ, Tarunina M, Green B and Robertson L (1994) Serum p53 autoantibodies: incidence in familial breast cancer. Eur J Cancer 30A: 580-584
10. Hanzal E, Gitsch G, Kohlberger P, Dadak CH, Miechowiecka N and Breitenecker G (1992) Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival. Anticancer Res 12: 2325-2330
11. Hollstein M, Sidransky D, Vogelstein B and Harris C (1991) p53 mutations in human cancers. Science 253: 252-254
12. Houbiers JGA, van der Burg SH, van de Watering LMG, Tollenaar RAEM, Brand A, van de Velde CJH and Melief CJM (1995) Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 72: 637-641
13. Isola J, Visakorpi T, Holli K and Kallioniemi O-P (1992) Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84: 1109-1114
14. Labrecque S, Naor N, Thomson D and Matlashewski G (1993) Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 53: 3468-3471
15. Lane DP and Benchimol S (1990) p53: oncogene or anti-oncogene. Genes Dev 4: 1-8
16. Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP and Soussi T (1995) p53 antibodies in patients with various types of cancer: assay, identification and characterization. Clin Cancer Res 1: 1463-1469
17. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M and Leinster SJ (1994) The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 69: 1115-1119
18. Noguchi M, Kitagawa H, Kinoshita K, Miyazaki I, Saito Y and Mizukami Y (1993) Prognostic significance of p53 and c-erbB-2 experience in operable breast cancer. Int J Oncol (Greece) 2: 587-591
19. Osborne RJ, Merlo GR, Mitsudomi T, Venesio T, Liscia DS, Cappa APM, Chiba I, Takahashi T, Nau MM, Callahan R and Minna JD (1991) Mutations in the p53 gene in primary human breast cancers. Cancer Res 51: 6194-6198
20. Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, Hennessy C, Lennard JW, Angus B and Horne HW (1991) p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 164: 75-81
21. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J and Soussi T (1995) Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 345: 621-622
22. Porzolt FMS, Hoher D, Muche D, Gaus W and Montenarth M (1994) Biological relevance of auto-antibodies against p53 in patients with metastatic breast cancer. Onkologie 17: 402-408
23. Regidor PA, Regidor M, Callies R and Schindler AE (1996) Detection of p53 autoantibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist? Eur J Gyanaecol Oncol 17: 192-199
24. Ryder SD, Rizzi PM, Volkmann M, Metivier E, Pereira LM, Galle PR, Naoumov NV, Zentgraf H and Williams R (1996) Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma. J Clin Pathol 49: 295-299
25. Schlichtholz B, Legros Y and Gillet D (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52: 6380-6384
26. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G and Veronesi U (1993) p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85: 965-970
27. Stenmark-Askmalm M, Stål O, Sulliwan S, Ferraud L, Xiao-Feng S, Carstensen J and Nordenskjöld B (1994) Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer 30A: 175-180
28. Thor AD, Moore DHI, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen L-C, Mayall BH and Smith HS (1992) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 84: 845-855
29. UICC (1982) TNM Classification of Malignant Tumours, 3rd edn. Springer Verlag, Geneva
30. Vojtesek B, Kovarik J, Dolezalova H, Nenutil R, Havlis P, Brentani RR and Lane DP (1995) Absence of p53 autoantibodies in a significant proportion of breast cancer patients. Br J Cancer 71: 1253-1256
31. Willsher PC, Pinder SE, Robertson L, Nicholson RI, Ellis IO, Bell JA, Blamey RW, Green JA and Robertson JF (1996) The significance of p53 autoantibodies in the serum of patients with breast cancer. Anticancer Res 16: 927-930
32. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF and Carbone DP (1992) Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52: 4168-4174